Q2 2021 Results - Reimagining Medicine

Participants Company overview Pharmaceuticals Oncology Financial review Conclusion Appendix References Financial performance Innovation: Pipeline overview Innovation: Clinical trials Solid H1 Innovative Medicines division performance Innovative Medicines Sandoz Group H1 2021 Net sales Core Oplnc Core Core margin change vs. PY % CC1 change vs. PY % CC1 margin change vs. PY %pts cc1 % 5 6 36.8 0.4 -5 -19 20.5 -3.7 3 2 32.7 -0.4 1. Core results, constant currencies and free cash flow are non-IFRS measures. Further details regarding non-IFRS measures can be found starting on page 48 of the Condensed Financial Report. 43 Investor Relations | Q2 2021 Results U NOVARTIS | Reimagining Medicine

View entire presentation